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Abstract Purpose In left-sided breast cancer radiotherapy,
tangential intensity modulated radiotherapy combined with
breath-hold enables a dose reduction to the heart and left
anterior descending (LAD) coronary artery. Aim of this
study was to investigate the added value of intensity modu-
lated proton therapy (IMPT) with regard to decreasing the
radiation dose to these structures. Methods In this compar-
ative planning study, four treatment plans were generated in
20 patients: an IMPT plan and a tangential IMRT plan, both
with breath-hold and free-breathing. At least 97 % of the
target volume had to be covered by at least 95 % of the
prescribed dose in all cases. Specifically with respect to the
heart, the LAD, and the target volumes, we analyzed the
maximum doses, the mean doses, and the volumes receiving
5–30 Gy. Results As compared to IMRT, IMPT resulted in
significant dose reductions to the heart and LAD-region even
without breath-hold. In the majority of the IMPT cases, a
reduction to almost zero to the heart and LAD-region was
obtained. IMPT treatment plans yielded the lowest dose to
the lungs. Conclusions With IMPT the dose to the heart and
LAD-region could be significantly decreased compared to
tangential IMRT with breath-hold. The clinical relevance
should be assessed individually based on the baseline risk of
cardiac complications in combination with the dose to organs
at risk. However, as IMPT for breast cancer is currently not
widely available, IMPT should be reserved for patients
remaining at high risk for major coronary events.
Keywords Breath-hold  Breast cancer  IMPT  IMRT 
Heart sparing
Introduction
Postoperative radiotherapy is considered standard of care after
breast-conserving surgery for breast cancer [1]. After mas-
tectomy, radiotherapy is required in case of intermediate or
high risk of locoregional failure [2, 3]. Previous studies [4, 5]
have shown that radiotherapy is associated with an increased
rate of major coronary events, especially in patients treated for
left-sided breast cancer. However, it should be noted that the
follow-up period in these studies is relatively short [4, 5]. With
improved survival, more patients will be at risk for long-term
radiation-induced toxicity, thus making it even more impor-
tant to reduce the dose to all organs at risk (OARs).
Recently, Darby et al. found that the rate of major
coronary events was proportional to the mean dose to the
heart starting within a few years after exposure. Patients
with pre-existing cardiac risk factors had higher absolute
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risks after radiotherapy than those without [6]. Given its
anatomical location, the left anterior descending (LAD)
coronary artery is most at risk for developing atheroscle-
rosis after left-sided breast-conserving radiotherapy [7].
Taylor et al. showed that even with contemporarily deliv-
ered tangential fields, the mean dose to the LAD was
considerable: 7.6 Gy. Furthermore, half of the patients
appeared to receive more than 20 Gy in the ventral part of
the heart [8]. As the rate of ischemic heart disease is pro-
portional to the mean heart dose, Darby et al. advised to
reduce the dose to the heart as much as possible. In order to
reduce the dose to the heart and the LAD using photons,
intensity modulated radiotherapy (IMRT), either combined
or not combined with breath-hold techniques, has been
investigated [9–11] and compared to 3D-conformal radio-
therapy (3D-CRT) with and without breath-hold [11].
A commonly used IMRT technique for breast cancer
treatment is an IMRT technique based on the standard
tangential fields with additional smaller subfields in order
to improve dose homogeneity [12]. The advantage of this
technique, compared to the full inversed planned multiple
beam IMRT, is, that the dose redistribution is confined to
the same area as the tangential fields, thus avoiding an
excessive low dose to surrounding OARs. In addition,
breath-hold techniques can be used to decrease the heart
dose. With a breath-hold technique, a patient holds her
breath during 25–30 s intervals in which radiation is
administered. In doing so, the distance between the heart
and the radiation fields increases and, consequently, the
dose to the heart decreases [10].
However, due to anatomical variations in some patients,
the radiation dose to the heart remains relatively high, even
with the use of advanced photon-based techniques. Due to
its physical characteristics, proton therapy may eventually
enable a further decrease of dose to the heart. In contrast to
a photon beam, a proton beam is characterized by a very
narrow width of a relatively high peak of maximum dose
administration: the Bragg peak. In other words, a proton
beam is characterized by a dose distribution that is finite
and adjustable in depth depending on the energy of the
proton beam. Theoretically, these characteristics of protons
enable a very precise irradiation of the target volume, while
at the same time better sparing of the surrounding normal
tissue can be obtained [13].
Therefore, we assumed that proton therapy may enable
an improved sparing of the heart and LAD in left-sided
breast cancer patients, especially in cases where the heart
dose remains (relatively) high with advanced photon
techniques [14–16]. In a previous paper, we found that
tangential IMRT in combination with a breath-hold pro-
cedure resulted in a significant decrease of the dose to the
heart and LAD-region compared to 3D-CRT in breath-
hold, while retaining optimal target volume coverage [11].
Furthermore, compared to standard photon 3D-CRT, tan-
gential IMRT improves overall cosmesis and reduces the
risk of skin telangiectasia [17]. However, to the best of our
knowledge, planning comparative studies are lacking,
which focus on the additional value of protons for whole
breast irradiation compared to that of tangential IMRT
(both with and without breath-hold).
Therefore, the aim of this planning comparative study
was to determine whether a further dose reduction to the
heart and LAD could be obtained with proton therapy
(either with or without breath-hold).
Methods
We used the same methods as described in our previous
planning comparative study comparing conformal photon
radiotherapy (3D-CRT) and tangential IMRT (with and
without breath-hold) [11]. The current study population con-
sisted of 20 consecutive female breast cancer patients (pT1-2;
pN0-1; M0). All patients underwent breast-conserving sur-
gery and axillary staging with a sentinel node procedure.
To avoid interobserver-based delineation differences,
the glandular breast tissue was contoured by one experi-
enced radiation oncologist (LKH), according to RTOG
delineation guidelines [18], and defined as the CTV. The
PTV was created by expanding the CTV with 5 mm in
transverse directions, 6 mm cranially, and 9 mm caudally
according to the guidelines of our department for 3D-CRT
and IMRT. The PTV was retracted 5 mm from the patient
surface (PTVtrim) to minimize high-dose levels in the build-
up regions for IMRT plans. No adaptations for PTVtrim
were performed in the direction of the lungs, in doing so
the thoracic wall may be included in PTVtrim. In order to be
able to compare the same volumes, we applied the same
margins to the proton plans. Furthermore, the heart and the
LAD-region were delineated by one experienced radiation
oncologist (LKH) and were subsequently reviewed by an
experienced cardiac radiologist (MH). All volumes were
delineated on each breath-hold scan and free-breathing
scan. For the breath-hold scan, the active breathing control
(ABC) method was used (ELEKTA Active Breathing
CoordinatorTM device, Crawley, United Kingdom) [19]. A
high feasibility rate was reported when using the ABC
method [10, 20]. Details concerning the ABC method were
described by Mast et al. [11].
Treatment planning techniques
Tangential IMRT-planning
All IMRT plans were produced by one experienced do-
simetrist (HR), who was blinded for the IMPT plans. The
34 Breast Cancer Res Treat (2014) 148:33–39
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applied IMRT technique was a tangential IMRT technique.
According to this technique, approximately 60 % of the
dose was given with two tangential open fields, and 40 %
with four inversely planned tangential IMRT fields using
the same gantry angles, with a ‘step-and-shoot’ technique
[11, 12]. The nominal energy used was 6 MV in most of
the cases, and occasionally 10 MV.
Proton planning
Spot scanning intensity modulated proton therapy (IMPT)
plans were planned by two experienced IMPT dosimetrists
(HC, PK) using a research version of the Pinnacle3 plan-
ning system (version 9.1, Philips Medical Systems, United
States). Both were blinded for the IMRT plans. With spot
scanning, a pencil beam of protons is regulated in a high-
dose spot. This spot can be positioned for a specified period
of time; by superimposing several spots, the desired radi-
ation dose can be composed. Generally, for protons a RBE
of 1.1 is used over the full depth of the proton beam, and
the dose is represented as CGE (cobalt gray equivalent,
which is RBE 9 physical dose in Gy) [15]. In the doses we
report here, this RBE has been taken into account.
IMPT dose calculations and field configurations were
planned according to Ares et al. [21]. In all plans, the
gantry angles were 345 (-15), 27, and 75. The dif-
ferent beams were set to distribute the spots in such a way
that no spot was more than 0.2 cm outside the PTVtrim.
Spots were placed over the PTVtrim with 8 mm separation
in the plane perpendicular to the beam direction; while in
depth, spot layers were positioned and interspaced with
5 mm between each spot.
Energy layers ranged from 7.7 to 23.0 g/cm2 (repre-
senting the depth of the Bragg peak location) or
100–185 MeV. Corresponding lateral spot sizes ranged
approximately from 15 to 8 mm full-width-at-half-max-
imum at the isocenter in air and without range shifter. A
range shifter of 75 mm water equivalent thickness was
used so that the spot positions ranged from 2 to 155 mm
water equivalent depth. Note that the range shifter and air
gap between range shifter and patient skin increase the spot
size.
All plans were adapted to the individual target volumes
and critical organs, using the ‘‘trial-and-error’’ method.
IMRT and IMPT treatment plan optimization
The prescribed dose was 42.56 Gy in 16 fractions in all
cases. For all IMRT and IMPT plans, 97 % of the PTVtrim
had to be covered by at least 95 % of the prescribed dose
with a maximum of 2 % receiving more than 107 % of the
prescribed dose [22]. No compromises on the PTV cover-
age with either of the techniques were made to ensure a fair
comparison. For the PTVtrim, the following constraints
were used: uniform dose (42.56 Gy), maximum dose
(45.5 Gy, point dose), and minimum dose (40.6 Gy). The
maximum dose (Dmax) was defined as the maximal dose to
a volume of at least 2 % of that specific volume; according
to the ICRU 83. All further planning objectives used were
similar again to obtain fair dosimetric comparisons
between the two techniques. For the purposes of our study,
IMRT and IMPT treatment plans based on the breath-hold
and free-breathing scans were compared in all patients.
Furthermore, various dose volume parameters of PTVtrim,
heart, LAD-region, and lung (both lungs as well as the left
lung separately) were generated and evaluated. The choice
of these dose volume parameters (Dmax; mean; V5–
V30 Gy) was based on those published in the literature [10,
22, 23]. Finally, all plans were evaluated and approved by
two experienced breast cancer radiation oncologists (HS
and JHM).
Statistics
A Wilcoxon signed-rank test was performed to compare
dose and volume differences since the number of eligible
cases was less than 30. For this analysis, we used SPSS
Statistics version 20.0. The level of statistical significance
was defined by a p value of B0.05 (two-sided) for all tests.
Results
Heart and LAD-region
The mean doses for the heart and LAD-region, for IMRT
and IMPT, in breath-hold and free-breathing, in all cases
are presented in Fig. 1.
Despite the use of tangential IMRT with breath-hold in
some patients, the dose to the LAD-region remained rela-
tively high (Table 1; Fig. 1). With breath-hold IMRT, still
9 out of 20 patients received a mean dose to the LAD-
region exceeding 5 Gy, while in 4 out of 20 patients the
dose remained beyond 10 Gy. In 3 patients, the mean heart
dose was more than 2 Gy (Fig. 1).
An additional reduction of the various dose parameters
could be obtained with IMPT as well as with breath-hold
IMPT. The volume of the heart and LAD-region receiving
20 Gy (V20 Gy) could be reduced to almost zero in all
patients (Figs. 1, 2; Table 1).
Lung
As compared to IMRT, the mean lung dose, the V5 Gy,
and the V20 Gy in both lungs and in the left lung could be
reduced significantly. In particular, the mean V20 Gy value
Breast Cancer Res Treat (2014) 148:33–39 35
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for both lungs could be reduced from 5.1 % (SD 2.2) with
breath-hold IMRT to 1.3 % (SD 0.8) with breath-hold
IMPT (Table 1).
Discussion
The main objective of this study was to investigate if the
dose to the heart and LAD-region could be reduced using
spot scanning IMPT. The results showed that, with both
IMPT techniques (with and without breath-hold), the doses
to the heart as well as to the LAD-region could be reduced
significantly compared to IMRT with breath-hold. This
could be achieved without compromising the doses to the
target volumes. It should be stressed that, with IMPT, a
further reduction to almost zero to the heart and LAD-
region could be obtained in the majority of cases. The
results show that a breath-hold technique had no added
value when using IMPT. However, using breath-hold may
improve the robustness of the IMPT technique, since the
tissue shift will be less in breath-hold. Protons are more
sensitive than photons to the effects of motion due to the
range of the Bragg Peak. When using a proton field from a
perpendicular direction, a tissue shift could cause thickness
changes and thus range changes.
Recently Darby et al. reported a dose–effect relationship
between the dose to the heart and the rate of major coro-
nary events [6]. The authors could not identify any
threshold dose for the development of coronary events,
emphasizing the need to reduce the dose to as low as
possible. The average mean heart dose of the left-sided
breast cancer patients in their cohort was 6.6 Gy [6].
However, we noted lower mean heart doses with our tan-
gential IMRT (2.7 Gy with free-breathing and 1.5 Gy with
breath-hold). With IMPT further reductions could be
obtained (0.2 Gy with free-breathing and 0.1 Gy with
breath-hold).
Our study compares two techniques using the same
fractionation scheme, with a fraction dose of 2.66 Gy and a
total dose of 42.65 Gy. However, if the effects on reduction
in cardiac dose of this study are being compared to the
results of other planning studies, this needs to be taken into
account.
It has been shown that decreasing of the mean heart dose
is relevant [6]. The lifetime risk of radiation-induced
ischemic heart disease for breast cancer patients increases
linearly with an increase of the mean dose to the heart of
7.4 % per Gy (95 % confidence interval, 2.9–14.5) [6].
Consequently, the baseline risk should be taken into
account. Recently, Duma et al. [24] approximated the
increased rate of absolute radiation-induced ischemic heart
disease by using the tables of the Darby publication [6].
They reported that, irradiating a 50-year-old breast cancer
patient without cardiac risk factors with a mean heart dose
of 3 Gy, the risk of having at least one acute coronary
event by the age of 80 years rises from 4.5 to 5.4 %. They
subsequently noted that in the presence of pre-existent
cardiac risk factors, the risk of having at least one acute
coronary event by the age of 80 years would rise from 8 to
9.7 %. If the mean heart dose would be 10 Gy and in the
presence of cardiac risk factors, this risk would increase
from 8 to 13.5 % [24]. Although, with breath-hold IMPT,
the mean heart dose could be reduced to almost zero, the
question arises whether all left-sided breast cancer patients
will have clinically relevant benefit from proton irradiation.
Recently, Langendijk et al. described the so-called model-
based approach, to define which patients could be selected
for proton therapy. In this model-based approach, the
estimated benefit in terms of risk reduction can be obtained
by integrating dose differences in prediction models [25].
The excess risk on ischemic heart disease depends on the
dose, and the relative increase per Gy is independent of the
baseline risk on cardiac events, meaning that the absolute
excess risk can be easily estimated by calculating the
baseline risk, e.g., the Reynolds score [26], in addition to
the mean heart dose.
Apart from the mean heart dose, there are data sug-
gesting that the dose to the LAD coronary artery is most at
risk for developing atherosclerosis after left-sided breast-
conserving radiotherapy due to its anatomical position in
Fig. 1 Isodose lines in the caudal part of the patient on the breath-
hold scan. Delineated organs at risk: white line heart; black line
region of the left anterior descending coronary artery. Planning target
volume: black line PTVtrim; thick white line 95 % isodose line. At the
bottom right, the used gantry angles were pointed out, represented by
the small arrows
36 Breast Cancer Res Treat (2014) 148:33–39
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relation to the breast [7]. In the current study, the average
mean dose to the LAD-region was 6.7 Gy with breath-hold
IMRT which could be reduced to 0.3 Gy with breath-hold
IMPT. These doses are lower when compared to the mean
LAD doses of 20 and 9.4 Gy, without using breath-hold [6,
8]. It should be noted that the methodologies of defining
the LAD or LAD-region varied widely among these three
studies [6, 8, 11].
As in most treatment planning comparative studies,
some critical notes also apply to this study.
First, set-up errors and geometric changes during radi-
ation treatment are more likely to affect the dose distri-
butions when using IMPT. It should be noted that the effect
of range uncertainties and patient breathing motion using
IMPT were relatively small, as shown by Ares et al. [21]
which is in line with the results of Xu et al. [27]. However,
Wang et al. compared a passive scattered proton beam with
a spot scanning IMPT technique and stated that IMPT is
more sensitive for set-up uncertainties and breathing
motion [28]. With advanced position verification proce-
dures and adaptive treatment strategies in combination with
a breath-hold technique, these uncertainties are expected to
be minimized. Furthermore, as pointed out by other
authors, set-up errors and range uncertainties need to be
accounted for by applying robust IMPT treatment planning
techniques rather than by using the traditional CTV-PTV
margin concept [29, 30].
Second, some authors reported higher skin dose when
using protons and, hence, worse cosmetic outcome can be
expected. Girodet et al. reported worse cosmetic outcome
in accelerated partial breast irradiation (APBI) when using
protons. However, they used a single field per treatment
Table 1 Dose distribution parameters averaged over 20 patients
Mean (SD) (n = 20) p value
BH FB BH compared to FB, for
both IMPT and IMRT
IMPT compared to IMRT,
for both BH and FB
IMPT IMRT IMPT IMRT
Heart
Mean (Gy) 0.1 (0) 1.5 (0.5) 0.2 (0.1) 2.7 (1.3) p \ 0.01 p \ 0.01
Dmax (Gy) 0.3 (0.3) 8.6 (6.2) 1.2 (1.7) 24.7 (14.7) p \ 0.01 p \ 0.01
V5 Gy (%) 0.1 (0.2) 2.5 (2.1) 0.5 (0.8) 7.4 (4.7) p \ 0.01 p \ 0.01
V20 Gy (%) 0 0.6 (0.8) 0.1 (0.2) 3.5 (3.0) IMPT: p = 0.02/IMRT: p \ 0.01 p \ 0.01
V30 Gy (%) 0 0.3 (0.4) 0 2.4 (2.3) IMPT: p = 1.80/IMRT: p \ 0.01 p \ 0.01
LAD-region
Mean (Gy) 0.3 (0.2) 6.7 (5.1) 0.7 (0.8) 14.9 (9.3) p \ 0.01 p \ 0.01
Dmax (Gy) 1.8 (1.9) 18.8 (13.6) 4.5 (3.4) 31.4 (13.0) p \ 0.01 p \ 0.01
V5 Gy (%) 0.4 (0.9) 30.3 (25.9) 2.8 (5.8) 54.9 (25.1) p \ 0.01 p \ 0.01
V10 Gy (%) 0.1 (0.3) 18.2 (21.5) 0.8 (2.7) 42.9 (26.6) IMPT: p = 0.04/IMRT: p \ 0.01 p \ 0.01
V20 Gy (%) 0 9.7 (15.1) 0.1 (0.6) 32.8 (27.1) IMPT: p = 0.06/IMRT: p \ 0.01 BH: p = 0.20/FB: p \ 0.01
Bilateral lung
Mean (Gy) 0.8 (0.4) 2.6 (0.9) 0.9 (0.3) 2.9 (1.1) IMPT: p = 0.10/IMRT: p \ 0.02 p \ 0.01
Dmax (Gy) 14.6 (8.0) 33.4 (5.7) 18.0 (6.9) 35.5 (5.0) p \ 0.05 p \ 0.01
V5 Gy (%) 3.6 (1.9) 10.1 (3.1) 4.0 (1.2) 10.1 (3.3) IMPT: p = 0.08/IMRT: p = 0.90 p \ 0.01
V20 Gy (%) 1.3 (0.8) 5.1 (2.2) 1.5 (0.7) 5.7 (2.6) IMPT: p = 0.06/IMRT: p = 0.03 p \ 0.01
Lung left
Mean (Gy) 1.5 (0.6) 5.4 (1.8) 1.6 (0.6) 6.1 (2.3) IMPT: p = 0.20/IMRT: p \ 0.01 p \ 0.01
Dmax (Gy) 23.6 (8.2) 37.1 (2.8) 27.0 (7.0) 38.7 (2.3) p \ 0.04 p \ 0.01
V5 Gy (%) 7.1 (2.7) 21.4 (6.6) 7.7 (2.7) 21.9 (7.1) IMPT: p = 0.17/IMRT: p = 0.59 p \ 0.01
V20 Gy (%) 2.5 (1.4) 10.9 (4.7) 2.8 (1.4) 12.4 (5.7) IMPT: p = 0.04/IMRT: p = 0.02 p \ 0.01
PTVtrim
V95 % (%) 99.6 (0.32) 97.9 (0.15) 99.7 (0.19) 97.9 (0.18) IMPT: p = 0.09/IMRT: p = 0.70 p \ 0.01
V107 % (%) 0 0.4 (1.0) 0 0.2 (0.4) IMPT: p = 1.00/IMRT: p = 0.47 p \ 0.02
Non-significant data is presented in bold
BH breath-hold, FB free-breathing, IMPT intensity modulated proton therapy, IMRT intensity modulated radiotherapy, V5, V10, V15, V20, V30,
and V40 Gy volume receiving C5, 10, 15, 20, 30, and 40 Gy, respectively, Dmax dose encompassing 2 % of the volume. V95 % and V107 %
volume receiving C95 and 107 % of the prescribed dose, respectively
Breast Cancer Res Treat (2014) 148:33–39 37
123
and stated that multiple proton beam scanning and advan-
ces in patient set-up could result in decreased margins [31].
In our planning comparative study, we were not able to
compare the dose to the skin since the treatment planning
system used is not able to adequately calculate the dose to
the skin. Therefore, the clinical experience when using
protons in breast cancer treatment is of importance. Several
phase II studies report on the cosmetic results after proton
beam therapy [31, 32].
Third, for the current study, we decided to use tangential
IMRT with 60 % of the dose given with two open tan-
gential fields. Further dose reductions to the heart could be
obtained by using IMRT with a larger degree of freedom.
However, in most cases this can only be achieved at the
expense of dose to other OARS and normal tissue [20, 33].
Ares et al. showed that, using proton irradiation, in left-
sided breast cancer the dose to the OARs can significantly be
reduced when compared to photons [21]. As yet, no planning
study has compared proton and photon irradiation in com-
bination with breath-hold in left-sided breast cancer radio-
therapy. In most departments, a 3D-CRT photon technique is
considered the current standard. However, recently it has
been shown that tangential IMRT with breath-hold further
reduces the dose to the heart and LAD-region without
increasing the dose to other normal tissues [11].
Based on the radiation principles that dose should be
‘‘As Low As Reasonably Achievable’’ (ALARA) there is
no doubt that patients will benefit from protons at least to
some extent. Due to limited accessibility of proton therapy
and higher costs, it will not be feasible to offer protons to
all breast cancer patients. A model-based approach will
enable the identification of patients who will benefit most
from this new technology and thus will ensure a more cost-
effective use. For all other left-sided breast cancer patients,
a tangential IMRT technique with breath-hold can be used
to reduce the dose to the heart and LAD-region. In future, it
may be possible to make choices based on individual
planning comparisons in order to individualize the radia-
tion treatment.
Conclusion
In left-sided breast cancer irradiation, IMPT is the most
promising technique to maximally reduce the dose to heart
and LAD-region, even without a breath-hold technique.
However, as IMPT for breast cancer is currently not widely
available, IMPT should be reserved for patients remaining
at high risk for major coronary events.
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